

LOOK FORWARD.

Dan Myers
Co-Founder, President and CEO

Ophthalmology Innovation Summit
October 16, 2014

Forward-Looking Statement

This presentation contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the regulatory status and potential commercialization of ILUVIEN in the 10 additional EU countries for which Alimera has applied for approval. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, uncertainty as to Alimera's ability to commercialize, and market acceptance of, ILUVIEN in the EU, Alimera's ability to obtain marketing authorization for ILUVIEN in additional EU countries, as well as other factors discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Alimera's Annual Report on Form 10-K for the year ended December 31, 2013 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2014, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov. In addition to the risks described above and in Alimera's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera's results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

36 Month Treatment for DME

- **ILUVIEN® (fluocinolone acetonide intravitreal implant)**
 - Corticosteroid for patients suffering from diabetic macular edema (DME)
 - Delivers a sustained, therapeutic effect for up to 36 months with one injection

OUS Commercialization Strategy

- **European Expansion**
 - Approved in ten countries; pending in seven countries
 - Commercially available in UK and Germany
- **Distribution partner in place for Australia and New Zealand**


US Strategy

- **Approved September 26, 2014**
- **Commence shipments by end of Q1 2015**
- **Broader label than Europe; increased patient opportunity**

ILUVIEN® is indicated for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

Why a Steroid for DME?


- Anti-VEGF antibody is standard of care, but doesn't work on everyone
- DME involves multiple cytokines in the disease that increase in importance



ILUVIEN Advantages

ADDRESSES DME THAT PERSISTS

50%



SUSTAINED THERAPEUTIC
EFFECT

36:1



CONVENIENT
APPLICATION




Treatment of DME: Large Global Market Opportunity

Retained Worldwide Rights


US/EU Opportunity Similar Size


\$8,000 - \$9,000 Price Point



Upcoming Milestones

- **Q4 2014:** Introduce ILUVIEN this week
- **Q4 2014:** Expand European footprint
- **Q4 2014:** Build U.S. commercial infrastructure
- **Q4 2014 – Q1 2015:** Pursue marketing approval in seven additional EU countries pursuant to Mutual Recognition Procedure
- **Q1 2015:** Commence ILUVIEN shipments in U.S.





LOOK FORWARD.

Dan Myers
Co-Founder, President and CEO

Ophthalmology Innovation Summit
October 16, 2014